Impaired metabolic reactivity to oxidative stress in early psychosis patients

Schizophrenia Bulletin

Volumn 40, Issue 5, 2014, Pages 973-983

  Fournier, Margot ^a   Ferrari, Carina ^a   Baumann, Philipp S ^a   Polari, Andrea ^a   Monin, Aline ^a   Bellier Teichmann, Tanja ^a   Wulff, Jacob ^b   Pappan, Kirk L ^b   Cuenod, Michel ^a   Conus, Philippe ^a   Do, Kim Q ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b METABOLON INC   (United States)

Author keywords

Arginine; Extrace llular matrix; Glutathione; Mental disorder; Metabolism; Phospholipid

Indexed keywords

ARGININE; COLLAGEN; HYDROXYPROLINE; PROLINE;

ADAPTATION; ADULT; ARTICLE; CELL MEMBRANE; CELL METABOLISM; CLINICAL ARTICLE; COLLAGEN METABOLISM; CONTROLLED STUDY; EXTRACELLULAR MATRIX; FEMALE; FIBROBLAST; FOLLOW UP; HIGH RISK PATIENT; HUMAN; HUMAN CELL; MALE; MENTAL PATIENT; METABOLITE; METABOLOMICS; OXIDATION REDUCTION REACTION; OXIDATIVE STRESS; PRIORITY JOURNAL; PSYCHOSIS; SCHIZOPHRENIA; GENETIC PREDISPOSITION; GENETICS; METABOLISM; PHYSIOLOGY; YOUNG ADULT;

ADAPTATION, PHYSIOLOGICAL; ADULT; CELL MEMBRANE; EXTRACELLULAR MATRIX; FEMALE; FIBROBLASTS; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; METABOLOMICS; OXIDATIVE STRESS; PSYCHOTIC DISORDERS; YOUNG ADULT;

EID: 84906938008     PISSN: 05867614     EISSN: 17451701     Source Type: Journal    
DOI: 10.1093/schbul/sbu053     Document Type: Article

References (76)

1. Do KQ, Cabungcal JH, Frank A, Steullet P, Cuenod M. Redox dysregulation, neurodevelopment, and schizophrenia. Curr Opin Neurobiol. 2009;19: 220-230.
2. Ben Othmen L, Mechri A, Fendri C, et al. Altered antioxidant defense system in clinically stable patients with schizophrenia and their unaffected siblings. Prog Neuropsychopharmacol Biol Psychiatry. 2008;32: 155-159.
3. Pedrini M, Massuda R, Fries GR, et al. Similarities in serum oxidative stress markers and inflammatory cytokines in patients with overt schizophrenia at early and late stages of chronicity. J Psychiatr Res. 2012;46: 819-824.
4. Yao JK, Reddy R, McElhinny LG, van Kammen DP. Reduced status of plasma total antioxidant capacity in schizophrenia. Schizophr Res. 1998;32: 1-8.
5. Zhang XY, Tan YL, Cao LY, et al. Antioxidant enzymes and lipid peroxidation in different forms of schizophrenia treated with typical and atypical antipsychotics. Schizophr Res. 2006;81: 291-300.
6. Do KQ, Trabesinger AH, Kirsten-Krüger M, et al. Schizophrenia: glutathione deficit in cerebrospinal fluid and prefrontal cortex in vivo. Eur J Neurosci. 2000;12: 3721-3728.
7. Gawryluk JW, Wang JF, Andreazza AC, Shao L, Young LT. Decreased levels of glutathione, the major brain antioxidant, in post-mortem prefrontal cortex from patients with psychiatric disorders. Int J Neuropsychopharmacol. 2011;14: 123-130.
8. Yao JK, Leonard S, Reddy R. Altered glutathione redox state in schizophrenia. Dis Markers. 2006;22: 83-93.
9. Prabakaran S, Swatton JE, Ryan MM, et al. Mitochondrial dysfunction in schizophrenia: evidence for compromised brain metabolism and oxidative stress. Mol Psychiatry. 2004;9: 684-97, 643.
10. Gysin R, Kraftsik R, Sandell J, et al. Impaired glutathione synthesis in schizophrenia: convergent genetic and functional evidence. Proc Natl Acad Sci U S A. 2007;104: 16621-16626.
11. Tosic M, Ott J, Barral S, et al. Schizophrenia and oxidative stress: glutamate cysteine ligase modifier as a susceptibility gene. Am J Hum Genet. 2006;79: 586-592.
12. Gysin R, Kraftsik R, Boulat O, et al. Genetic dysregulation of glutathione synthesis predicts alteration of plasma thiol redox status in schizophrenia. Antioxid Redox Signal. 2011;15: 2003-2010.
13. Kulak A, Steullet P, Cabungcal JH, et al. Redox dsregulation in the pathophysiology of schizophrenia and bipolar disorder: insights from animal models. Antiox redox signal. 2013;18: 1423-1443.
14. Cabungcal JH, Steullet P, Kraftsik R, Cuenod M, Do KQ. Early-life insults impair parvalbumin interneurons via oxidative stress: reversal by N-acetylcysteine. Biol Psychiatry. 2013;73: 574-582.
15. Lataster T, Valmaggia L, Lardinois M, van Os J, Myin- Germeys I. Increased stress reactivity: a mechanism specifically associated with the positive symptoms of psychotic disorder. Psychol med. 2013;43: 1389-1400.
16. Myin-Germeys I, Peeters F, Havermans R, et al. Emotional reactivity to daily life stress in psychosis and affective disorder: an experience sampling study. Acta Psychiatr Scand. 2003;107: 124-131.
17. Davis KL, Kahn RS, Ko G, Davidson M. Dopamine in schizophrenia: a review and reconceptualization. Am J Psychiatry. 1991;148: 1474-1486.
18. Glenthøj BY. The brain dopaminergic system. Pharmacological, behavioural and electrophysiological studies. Dan Med Bull. 1995;42: 1-21.
19. Laruelle M. The role of endogenous sensitization in the pathophysiology of schizophrenia: implications from recent brain imaging studies. Brain Res Brain Res Rev. 2000;31: 371-384.
20. Laruelle M, Abi-Dargham A. Dopamine as the wind of the psychotic fire: new evidence from brain imaging studies. J Psychopharmacol. 1999;13: 358-371.
21. Lataster J, Collip D, Ceccarini J, et al. Psychosocial stress is associated with in vivo dopamine release in human ventromedial prefrontal cortex: a positron emission tomography study using [8F]fallypride. Neuroimage. 2011;58: 1081-1089.
22. Myin-Germeys I, Marcelis M, Krabbendam L, Delespaul P, van Os J. Subtle fluctuations in psychotic phenomena as functional states of abnormal dopamine reactivity in individuals at risk. Biol Psychiatry. 2005;58: 105-110.
23. Hastings TG. The role of dopamine oxidation in mitochondrial dysfunction: implications for Parkinson's disease. J Bioenerg Biomembr. 2009;41: 469-472.
24. Kaddurah-Daouk R, McEvoy J, Baillie R, et al. Impaired plasmalogens in patients with schizophrenia. Psychiatry Res. 2012;198: 347-352.
25. Kaddurah-Daouk R, McEvoy J, Baillie RA, et al. Metabolomic mapping of atypical antipsychotic effects in schizophrenia. Mol Psychiatry. 2007;12: 934-945.
26. Orešic M, Seppänen-Laakso T, Sun D, et al. Phospholipids and insulin resistance in psychosis: a lipidomics study of twin pairs discordant for schizophrenia. Genome Med. 2012;4: 1.
27. Orešic M, Tang J, Seppänen-Laakso T, et al. Metabolome in schizophrenia and other psychotic disorders: a general population- based study. Genome Med. 2011;3: 19.
28. He Y, Yu Z, Giegling I, et al. Schizophrenia shows a unique metabolomics signature in plasma. Transl Psychiatry. 2012;2: e149.
29. Yang J, Chen T, Sun L, et al. Potential metabolite markers of schizophrenia. Mol Psychiatry. 2013;18: 67-78.
30. Pinkus R, Weiner LM, Daniel V. Role of oxidants and antioxidants in the induction of AP-1, NF-kappaB, and glutathione S-transferase gene expression. J Biol Chem. 1996;271: 13422-13429.
31. Prestera T, Holtzclaw WD, Zhang Y, Talalay P. Chemical and molecular regulation of enzymes that detoxify carcinogens. Proc Natl Acad Sci U S A. 1993;90: 2965-2969.
32. Schilderman PA, van Maanen JM, ten Vaarwerk FJ, et al. The role of prostaglandin H synthase-mediated metabolism in the induction of oxidative DNA damage by BHA metabolites. Carcinogenesis. 1993;14: 1297-1302.
33. Auburger G, Klinkenberg M, Drost J, et al. Primary skin fibroblasts as a model of Parkinson's disease. Mol Neurobiol. 2012;46: 20-27.
34. Mytilineou C, Werner P, Molinari S, Di Rocco A, Cohen G, Yahr MD. Impaired oxidative decarboxylation of pyruvate in fibroblasts from patients with Parkinson's disease. J Neural Transm Park Dis Dement Sect. 1994;8: 223-228.
35. Wiedemann FR, Winkler K, Lins H, Wallesch CW, Kunz WS. Detection of respiratory chain defects in cultivated skin fibroblasts and skeletal muscle of patients with Parkinson's disease. Ann N Y Acad Sci. 1999;893: 426-429.
36. Yung AR, Yuen HP, McGorry PD, et al. Mapping the onset of psychosis: the Comprehensive Assessment of At-Risk Mental States. Aust N Z J Psychiatry. 2005;39: 964-971.
37. Baumann PS, Crespi S, Marion-Veyron R, et al. Treatment and early intervention in psychosis program (TIPPLausanne): implementation of an early intervention programme for psychosis in Switzerland. Early Interv Psychiatry. 2013;7: 322-328.
38. Preisig M, Fenton BT, Matthey ML, Berney A, Ferrero F. Diagnostic interview for genetic studies (DIGS): inter-rater and test-retest reliability of the French version. Eur Arch Psychiatry Clin Neurosci. 1999;249: 174-179.
39. Evans AM, DeHaven CD, Barrett T, Mitchell M, Milgram E. Integrated, nontargeted ultrahigh performance liquid chromatography/ electrospray ionization tandem mass spectrometry platform for the identification and relative quantification of the small-molecule complement of biological systems. Anal Chem. 2009;81: 6656-6667.
40. Ohta T, Masutomi N, Tsutsui N, et al. Untargeted metabolomic profiling as an evaluative tool of fenofibrateinduced toxicology in Fischer 344 male rats. Toxicol Pathol. 2009;37: 521-535.
41. Lu C, King RD. An investigation into the population abundance distribution of mRNAs, proteins, and metabolites in biological systems. Bioinformatics. 2009;25: 2020-2027.
42. Storey JD, Tibshirani R. Statistical significance for genomewide studies. Proc Natl Acad Sci U S A. 2003;100: 9440-9445.
43. Andreasen NC, Pressler M, Nopoulos P, Miller D, Ho BC. Antipsychotic dose equivalents and dose-years: a standardized method for comparing exposure to different drugs. Biol Psychiatry. 2010;67: 255-262.
44. Davis JM, Chen N. Dose response and dose equivalence of antipsychotics. J Clin Psychopharmacol. 2004;24: 192-208.
45. Horrobin DF. Schizophrenia as a membrane lipid disorder which is expressed throughout the body. Prostaglandins Leukot Essent Fatty Acids. 1996;55: 3-7.
46. Keshavan MS, Mallinger AG, Pettegrew JW, Dippold C. Erythrocyte membrane phospholipids in psychotic patients. Psychiatry Res. 1993;49: 89-95.
47. Mahadik SP, Mukherjee S, Correnti EE, et al. Plasma membrane phospholipid and cholesterol distribution of skin fibroblasts from drug-naive patients at the onset of psychosis. Schizophr Res. 1994;13: 239-247.
48. Yao JK, Leonard S, Reddy RD. Membrane phospholipid abnormalities in postmortem brains from schizophrenic patients. Schizophr Res. 2000;42: 7-17.
49. Kato T, Shioiri T, Murashita J, Hamakawa H, Inubushi T, Takahashi S. Lateralized abnormality of high-energy phosphate and bilateral reduction of phosphomonoester measured by phosphorus-31 magnetic resonance spectroscopy of the frontal lobes in schizophrenia. Psychiatry Res. 1995;61: 151-160.
50. Pettegrew JW, Keshavan MS, Panchalingam K, et al. Alterations in brain high-energy phosphate and membrane phospholipid metabolism in first-episode, drug-naive schizophrenics. A pilot study of the dorsal prefrontal cortex by in vivo phosphorus 31 nuclear magnetic resonance spectroscopy. Arch Gen Psychiatry. 1991;48: 563-568.
51. Potwarka JJ, Drost DJ, Williamson PC, et al. A 1H-decoupled 31P chemical shift imaging study of medicated schizophrenic patients and healthy controls. Biol Psychiatry. 1999;45: 687-693.
52. Shioiri T, Someya T, Murashita J, et al. Multiple regression analysis of relationship between frontal lobe phosphorus metabolism and clinical symptoms in patients with schizophrenia. Psychiatry Res. 1997;76: 113-122.
53. Stanley JA, Williamson PC, Drost DJ, et al. Membrane phospholipid metabolism and schizophrenia: an in vivo 31P-MR spectroscopy study. Schizophr Res. 1994;13: 209-215.
54. Williamson PC, Brauer M, Leonard S, Thompson T, Drost D. 31P magnetic resonance spectroscopy studies in schizophrenia. Prostaglandins Leukot Essent Fatty Acids. 1996;55: 115-118.
55. Stanley JA, Williamson PC, Drost DJ, et al. An in vivo study of the prefrontal cortex of schizophrenic patients at different stages of illness via phosphorus magnetic resonance spectroscopy. Arch Gen Psychiatry. 1995;52: 399-406.
56. Arvindakshan M, Ghate M, Ranjekar PK, Evans DR, Mahadik SP. Supplementation with a combination of omega-3 fatty acids and antioxidants (vitamins E and C) improves the outcome of schizophrenia. Schizophr Res. 2003;62: 195-204.
57. Bentsen H, Solberg DK, Refsum H, et al. Bimodal distribution of polyunsaturated fatty acids in schizophrenia suggests two endophenotypes of the disorder. Biol Psychiatry. 2011;70: 97-105.
58. Glen AI, Glen EM, Horrobin DF, et al. A red cell membrane abnormality in a subgroup of schizophrenic patients: evidence for two diseases. Schizophr Res. 1994;12: 53-61.
59. Hoen WP, Lijmer JG, Duran M, Wanders RJ, van Beveren NJ, de Haan L. Red blood cell polyunsaturated fatty acids measured in red blood cells and schizophrenia: a meta-analysis. Psychiatry Res. 2013;207: 1-12.
60. Khan MM, Evans DR, Gunna V, Scheffer RE, Parikh VV, Mahadik SP. Reduced erythrocyte membrane essential fatty acids and increased lipid peroxides in schizophrenia at the never-medicated first-episode of psychosis and after years of treatment with antipsychotics. Schizophr Res. 2002;58: 1-10.
61. Peet M, Laugharne J, Rangarajan N, Horrobin D, Reynolds G. Depleted red cell membrane essential fatty acids in drug-treated schizophrenic patients. J Psychiatr Res. 1995;29: 227-232.
62. van der Kemp WJ, Klomp DW, Kahn RS, Luijten PR, Hulshoff Pol HE. A meta-analysis of the polyunsaturated fatty acid composition of erythrocyte membranes in schizophrenia. Schizophr Res. 2012;141: 153-161.
63. Grignon S, Chianetta JM. Assessment of malondialdehyde levels in schizophrenia: a meta-analysis and some methodological considerations. Prog Neuropsychopharmacol Biol Psychiatry. 2007;31: 365-369.
64. Zhang M, Zhao Z, He L, Wan C. A meta-analysis of oxidative stress markers in schizophrenia. Sci China Life Sci. 2010;53: 112-124.
65. Kano S, Colantuoni C, Han F, et al. Genome-wide profiling of multiple histone methylations in olfactory cells: further implications for cellular susceptibility to oxidative stress in schizophrenia. Mol Psychiatry. 2013;18: 740-742.
66. Mahadik SP, Mukherjee S, Wakade CG, Laev H, Reddy RR, Schnur DB. Decreased adhesiveness and altered cellular distribution of fibronectin in fibroblasts from schizophrenic patients. Psychiatry Res. 1994;53: 87-97.
67. Schwarz E, Guest PC, Steiner J, Bogerts B, Bahn S. Identification of blood-based molecular signatures for prediction of response and relapse in schizophrenia patients. Transl Psychiatry. 2012;2: e82.
68. Benedikt J, Inyushin M, Kucheryavykh YV, et al. Intracellular polyamines enhance astrocytic coupling. Neuroreport. 2012;23: 1021-1025.
69. Aricioglu F, Altunbas H. Is agmatine an endogenous anxiolytic/ antidepressant agent? Ann N Y Acad Sci. 2003;1009: 136-140.
70. Williams K. Modulation and block of ion channels: a new biology of polyamines. Cell Signal. 1997;9: 1-13.
71. Zeidan MP, Zomkowski AD, Rosa AO, Rodrigues AL, Gabilan NH. Evidence for imidazoline receptors involvement in the agmatine antidepressant-like effect in the forced swimming test. Eur J Pharmacol. 2007;565: 125-131.
72. Zomkowski AD, Santos AR, Rodrigues AL. Putrescine produces antidepressant-like effects in the forced swimming test and in the tail suspension test in mice. Prog Neuropsychopharmacol Biol Psychiatry. 2006;30: 1419-1425.
73. MacAllister RJ, Parry H, Kimoto M, et al. Regulation of nitric oxide synthesis by dimethylarginine dimethylaminohydrolase. Br J Pharmacol. 1996;119: 1533-1540.
74. Shahani N, Sawa A. Nitric oxide signaling and nitrosative stress in neurons: role for S-nitrosylation. Antioxid Redox Signal. 2011;14: 1493-1504.
75. Yao JK, Leonard S, Reddy RD. Increased nitric oxide radicals in postmortem brain from patients with schizophrenia. Schizophr Bull. 2004;30: 923-934.
76. Cabungcal JH, Steullet P, Morishita H, et al. Perineuronal nets protect fast-spiking interneurons against oxidative stress. Proc Natl Acad Sci U S A. 2013;110: 9130-9135.